# EHA Research Conference 2027

# "RNA Matters: From basic biology to therapeutics in hematology"

## Abstract Submission Guidelines

The abstract submission guidelines of the EHA Research Conference "RNA Matters: From basic biology to therapeutics in hematology" (EHA ReCon 2027) are intended to provide clear instructions before submitting an abstract. **You are kindly requested to carefully read the guidelines stated below.**

EHA and the Scientific Program Committee (SPC) of ReCon 2027 maintain the right to reject any abstract that does not meet the below requirements.

## Table of Contents


Abstract Submission Key Dates ..... 2
Deadlines Abstract Submission ..... 2
Terms & Conditions ..... 2
Applicable Law and Jurisdiction ..... 3
Submission Guidelines ..... 3
Abstract Topics ..... 4
Submission Specifications ..... 4
Abstract Review, Selection, and Publication ..... 5
Travel awards ..... 5

## Abstract Submission Key Dates

| | |
|---|---|
| July 15, 2026 | Abstract submission opens |
| **November 20, 2026 (23:59 CET)** | **First deadline of abstract submission – Oral & poster presentations** |
| December 9, 2026 | First round abstract allocation notification – Oral & poster presentations |
| December 17, 2026 (23:59 CET) | Deadline of withdrawal for first round abstract submission |
| **January 8, 2027 (23:59 CET)** | **Second deadline of abstract submission – Poster presentations only** |
| January 26, 2027 | Second round abstract allocation notification – Poster presentations & Poster pitches only |
| February 1, 2027 (23:59 CET) | Deadline of withdrawal for second round abstract submission |

## Deadlines Abstract Submission

There are **two deadlines** for abstract submission of ReCon 2027, which are **November 20, 2026 (23:59 CET)** and **January 8, 2027 (23:59 CET)**. Submissions received after January 8, 2027 (23:59 CET) will not be considered.

- **First abstract submission deadline – Oral and poster presentations**
  - Submission duration: July 15, 2026 – November 20, 2026 (23:59 CET)
  - Submissions will be considered for oral or poster presentations
  - Authors will be informed about the allocation by December 9, 2026
- **Second abstract submission deadline – Poster presentations only**
  - Submission duration: November 21, 2026 – January 8, 2027 (23:59 CET)
  - Submissions will be considered for poster presentations only
  - Authors will be informed about the allocation by January 26, 2027
  - Posters allocated a poster pitch will be notified by January 26, 2027 (submissions from both rounds are eligible)

Presenters, both oral and poster, must be registered for ReCon 2027 and have the chance to register at the Early Registration Fee (until January 8, 2027). Presenters of an abstract accepted during the second round will receive a discount code to register for the meeting with the Early Registration Fee; the discount code will expire on February 4, 2027 (23:59 CET).

## Terms & Conditions

1. The SPC encourages the submission of original scientific material unpublished at the time of the abstract submission deadline(s):

   a. Abstracts submitted to regional or national hematology meetings can be submitted to the EHA Research Conference for inclusion in the program;
   b. Abstracts submitted to large international meetings which are organized in the same period as the EHA Research Conference (February – April 2027) are allowed to be submitted to the meeting.
   c. Abstracts submitted to other large international meetings may also be submitted providing a clear indication about significant novel or updated information included in the appropriate abstract submission field.
2. Authors of submitted abstracts shall be the sole and exclusive owner of the abstract and all associated intellectual property rights. By submitting the abstract to EHA, the author grants EHA the right to use and (commercial) reprint the abstract in relation to the EHA Research Conference. Authors of submitted abstracts understand and agree that EHA will not pay compensation for this license.
3. Authors of submitted abstracts guarantee that the abstract (and all associated intellectual property rights) is free of any third-party rights to the fullest extent permitted by law, including but not limited to, inventor's rights of remuneration and any other ancillary rights.
4. By submitting an abstract, the submitting author confirms that they have approval from all the co-authors to submit and use the data in the abstract.
5. Submitted abstracts are considered embargoed from the time of submission. The embargo is lifted at the start of the conference.
6. Please do not submit the same study in multiple abstracts. Abstracts that appear as more than one version of a single study will be rejected.
7. Similarly, abstracts or (close) copies, may not be submitted under more than 1 (one) topic.

## Applicable Law and Jurisdiction

The above Terms and conditions are governed by the laws of the Netherlands. Any dispute related to these terms and conditions and the use or publication of the abstract shall be exclusively submitted to the District Court in the Hague, the Netherlands.

## Submission Guidelines

The submitted abstracts and cases should fully adhere to the guidelines below:

1. Abstracts should be submitted in clear (American) English to allow the reviewers to focus on the scientific content of the abstract. Non-English-speaking authors are encouraged to have their abstract checked for grammar and spelling.
2. The SPC assumes all presenting authors have proficiency in English and, thus are able to present and respond to questions.

3. In clinical studies, please state whether informed consent was obtained from patients.
4. The title and text may not contain trade names. The SPC reserves the right to replace trade names in accepted abstracts.
5. If off label use of drugs was involved, please state this clearly.
6. Withdrawal policy:
   If authors wish to withdraw their abstracts from presentation or publication, they are requested to send a letter via e-mail to the EHA Executive Office (eharecon@ehaweb.org). Consequently, the abstract will not be presented nor published.
   - Abstracts submitted before November 20, 2026 (23:59 CET):
     Withdrawal letter (if applicable) should be sent to the EHA Executive Office by **December 17, 2026 (23:59 CET)**
   - Abstracts submitted from November 21, 2026, until January 8, 2027 (23:59 CET):
     Withdrawal letter (if applicable) should be sent to the EHA Executive Office by **February 4, 2027 (23:59 CET)**

## Abstract Topics

Please select the most appropriate topic during the abstract and case submission:

1. RNA modifications and RNA binding proteins in hematological diseases
2. Altered RNA-biogenesis in hematology
3. lncRNAs and circRNAs: new regulatory functions and biomarker potential
4. RNA therapeutics in hematological diseases
5. RNA and immune and tumor microenvironment modulation
6. Synthetic and AI-based approaches in RNA medicine

## Submission Specifications

- Title count: max. 300 characters incl. space.
- Character limit: 3500 characters (incl. spaces & punctuation / excl. headers in the template).
- Please use the following subheadings: Background / Aims / Methods / Results / Summary - Conclusion
- Images have to be submitted as JPEG, tif, or gif files:
  - Due to limited space, only a simple graph/image can be submitted.
  - Images and graphs should reproduce well in black and white.
  - Image file should not exceed 500KB.
- Authors: There is no limit to the number of authors.
- References are obligatory when submitting an abstract

## Abstract Review, Selection, and Publication

1. All submitted abstracts will be reviewed by members of the Scientific Program Committee and selected faculty of the EHA Research Conference.
2. Abstracts may be selected for
    a. Oral presentation
    b. Poster presentation
        i. With or without poster pitch
    c. Rejection
3. Only the submitting author will receive a confirmation letter of acceptance for oral presentation, poster presentation, or a notice of rejection, by e-mail by **December 9, 2026,** or **January 26, 2027**, according to the abstract submission time.
    a. Note that it is the submitting author's responsibility to inform the presenting author of the abstract allocation outcome and ensure the presenting author is registered to the meeting.
4. Oral abstract presenters (excluding poster pitch presenters) must register themselves for EHA ReCon 2027. A code will be provided by EHA after the notification in order to register without charge.
5. Poster presenters must be registered for EHA ReCon 2027 in order to present.
    a. Presenters can register at the Early Fee. Presenters of abstracts submitted during the second period will receive a discount code for this.
6. The best abstracts scored as a poster presentation will be selected for an oral 'pitch' presentation, in addition to having a poster in the poster area.
    a. Authors of abstracts selected for a 'pitch' presentation will be informed when notification for the second abstract submission period goes out.
7. All presenters will be informed about the date and time of their session, and receive guidelines for their presentation.
8. All accepted abstracts will be published in the digital abstract book for meeting attendees. Note that after publication, the abstracts cannot be modified.

## Travel awards

For abstract submitters who are awarded a **poster presentation** there are 5 (five) travel awards made available by EHA's journal, HemaSphere. Each award consists of:

- €500 EURO award (flat rate)
- Award can be used for travel or accommodation, this is up to the applicant
- The award is given on a reimbursement basis, after the conference has ended
    - A link to request this reimbursement will be provided by EHA

There are 2 (two) types of travel awards:

1. 2 (two) awards reserved top scoring posters

2. 3 (three) awards reserved for submitters from lower income countries

The eligibility criteria for category 1 are as follows:

- Abstracts submitters must indicate in the submission form that they wish to be considered for a travel award
- Only those selected for a poster presentation (with or without pitch) are eligible
- Must have attended EHA ReCon 2027 in Malta

The eligibility criteria for category 2 are as follows:

- Submitters must reside in a lower income country
    - Eligibility is based on the IMF classification of 2026 for GDP per capita (link)
    - Eligible countries have a GDP per capita under $25000
- Abstracts submitters must indicate in the submission form that they wish to be considered for a travel award
- Only those selected for a poster presentation (with or without pitch) are eligible
- Must have attended EHA ReCon 2027 in Malta

The eligible submitters in category 2 will be reviewed by the EHA ReCon SPC and representatives from HemaSphere to determine selection, also considering the average review score.

Notification of awards will be sent together with the notifications after the second abstract submission round. Submissions from the first round will be considered.